BELVIN MARCIA 4

What Happened
Marcia Belvin, SVP and Chief Scientific Officer at CytomX Therapeutics (CTMX), received equity awards on February 2, 2026: 60,000 restricted stock units (RSUs) and 250,000 derivative securities (reported as an award/derivative). Both grants show an acquisition price of $0.00 (typical for compensation awards), for a total of 310,000 shares subject to future vesting rather than an open-market purchase or sale.

Key Details

• Transaction date: February 2, 2026; Form 4 filed February 4, 2026 (within the two-business-day Form 4 window).
• Grants reported: 60,000 RSUs (Footnote F1) and 250,000 derivative awards (listed as “Derivative”) — acquisition price $0.00 for each grant.
• Footnote F1: The 60,000 RSUs convert 1:1 to common shares when vested; 1/3 of those RSUs vest annually on March 15, starting March 15, 2027, subject to continued service.
• Footnote F3: The 250,000 derivative award vests 1/48th monthly beginning Feb 2, 2026 (Vesting Commencement Date), fully vesting after four years, subject to continued service.
• Footnote F2: Filing notes “Includes 218,958 RSUs” (this relates to reported holdings in the filing). The filing does not list a complete post-transaction total of common shares beneficially owned beyond the footnoted RSU amount.
• No sale or open-market purchase was reported — these are compensation grants.

Context

• These awards are compensation grants, not purchases; they carry vesting conditions and do not represent immediately tradable shares until vested (and, for options/derivatives, exercised if applicable).
• For retail investors, grants signal continued compensation alignment with management but are routine and subject to service/vesting requirements; they do not by themselves indicate a buy or sell decision by the insider.